OncoMatch/Clinical Trials/NCT06587867
Seronegative Myasthenia Gravis - Efgartigimod IV
Is NCT06587867 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies efgartigimod for efgartigimod.
Treatment: efgartigimod — This is to study the efficacy, safety and tolerability of efgartigimod in patients with seronegative generalized myasthenia gravis. This is an open label study. There will be 30 participants to enroll at University Health Network Toronto General Hospital. Study duration is 43 weeks from screening to end of study.
Check if I qualifyExtracted eligibility criteria
Prior therapy
Cannot have received: rituximab (rituximab)
Patients who have received rituximab or eculizumab in the 6 months before screening
Cannot have received: eculizumab (eculizumab)
Patients who have received rituximab or eculizumab in the 6 months before screening
Cannot have received: intravenous immunoglobulin (intravenous immunoglobulin)
Patients who had intravenous immunoglobulin or plasma exchange within 4 weeks of screening
Cannot have received: plasma exchange (plasma exchange)
Patients who had intravenous immunoglobulin or plasma exchange within 4 weeks of screening
Lab requirements
Kidney function
Cr >1.5 x elevated at screening [excluded]
Liver function
transaminases > 2.5 x elevation at screening [excluded]
Patients with renal/hepatic function impairment as defined by (Cr>1.5 x elevated) and/or (transaminases > 2.5 x elevation) at screening.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify